Quality of Life among Hepatocellular Carcinoma Patients Who Receive Initial Transcatheter Arterial Chemoembolization
Keywords:Hepatocellular carcinoma, Chemotherapy, Transcatheter arterial embolization, Quality of life
Quality of life is an important indicator of quality in nursing care for hepatocellular carcinoma patients, who have received Transcatheter Arterial Chemoembolization (TACE). This descriptive research aimed to compare the quality of life among hepatocellular carcinoma patients, before and after receiving initial TACE. Data were collected at a university hospital in southern Thailand, from November 2017 to October 2018. Sixty-five hepatocellular carcinoma patients were recruited. Research instruments included the EORTC QLQ-C30 and HCC18. Cronbach’s alphas for the EORTC QLQ-C30 and HCC18 questionnaires were 0.79 and 0.80, respectively. Data were analyzed using descriptive statistics and paired t-test.
Initial scores before receiving TACE were of a moderate level ( =3.49, S.D.=0.43), while after receiving TACE for 4 weeks, the mean score was at a high level ( =5.34, S.D.=0.42). Mean scores of global health status, post-TACE at 4 weeks, were significantly and statistically higher than pre- TACE scores (p<0.001).
The results suggest that TACE improves the quality of life and global health status among hepatocellular carcinoma patients, particularly through emotional-functioning dimensions. In order to improve the quality of life in hepatocellular carcinoma patients receiving TACE, it is essential for nurses to provide information and consultancy continuously.
Mohammadian M, Mahdavifar N, Mohahhadian-Hafshejani A, Salehini H. Liver cancer in the world: epidemiology, incidence, mortality and risk factors. WCRJ 2018; 5 (2): e1082.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): 359-86.
Virani S, Bilheem S, Chansaard W, Chitapanarux I, Daoprasert K, Khuanchana S, et al. National and subnational population-based incidence of cancer in Thailand: assessing cancers with the highest burdens. Cancers 2017; 9(8): e108
Daher S, Massarwa M, Benson AA, Khoury T. Current and future treatment of hepatocellular carcinoma: an updated comprehensive review. J Clin Transl Hepatol 2018; 6(1): 69-78.
Yi PS, Zhang M, Zhao JT, Xu MQ. Liver resection for intermediate hepatocellular carcinoma. World J Hepatol 2016 8(14): 607-15.
Roayaie S. TACE vs. surgical resection for BCLC stage B HCC. J Hepatol 2014; 61(1): 3-4.
Raoul JL, Forner A, Bolondi L, Cheung TT, Kloeckner R, de Baere T. Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. Cancer Treat Rev 2019; 72: 28-36.
Guan YS, He Q, Wang MQ. Transcatheter arterial chemoembolization: history for more than 30 years. ISRN Gastroenterol 2013; 480650.
Chhaniwal N, Li C, Wang J, Qiang G, Qi T, Maher H. Hepatocellular carcinoma: review of current treatment with a focus on transarterial chemoembolization and radiofrequency ablation. Open J Radiology 2015; 5(1): 50-8.
Mason MC, Massarweh NN, Salami A, Sultenfuss MA, Anaya DA. Post-embolization syndrome as an early predictor of overall survival after transarterial chemoembolization for hepatocellular carcinoma. HPB (Oxford) 2015; 17(12): 1137-44.
Cao W, Li J, Hu C, Shen J, Liu X, Xu Y, Ye Z. Symptom clusters and symptom interference of HCC patients undergoing TACE: a cross-sectional study in China. Support Care Cancer 2013; 21(2): 475-83.
Aroon N., Pongsri S., Kessiri W., Somrach T. Factors predicting quality of life of hepatocellular carcinoma patients undergoing transarterial chemoembolisation. Thai J of Nursing Council 2019; 34(2): 127-40. (in Thai)
Wongchan P. Best nursing practice in cancer care. Chanmaung Prining: Songkhla; 2011. (in Thai)
Shun SC, Chen CH, Sheu JC, Liang JD, Yang JC, Lai YH. Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist 2012; 17(5): 732-9.
Hinrichs JB, Hasdemir DB, Nordlohne M, Schweitzer N, Wacker F, Vogel A, et al. Health-related quality of life in patients with hepatocellular carcinoma treated with initial transarterial chemoembolization. Cardiovasc Intervent Radiol 2017; 40(10) :1559-66.
Suthisa T, Indicator report of advanced nurse practitioner, Nursing Services Division, Songklanagarind Hospital; 2017. (in Thai)
Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, et al. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol 2010; 21(7): 1024 -30.
Silpakit C, Sirilerttrakul S, Jirajarus M, Sirisinha T, Sirachainan E, Ratanatharathorn V. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30): validation study of the Thai version. Qual Life Res 2006; 15(1): 167-72.
Polit FD, Beck TC. Inferential statistic: Nursing research generating and assessing evidence for nursing practice. 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2012. p 404-32.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5(6): 649-55.
Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 2016; 64(1): 106-16.
Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150(4): 835-53.
Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg 2016; 2016: 1-9. doi.org/10.1155/2016/6120143
Eltawil KM, Berry R, Abdolell M, Molinari M. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. HPB (Oxford) 2012; 14(5): 341-50.
Steel J, Hess SA, Tunke L, Chopra K, Carr BI. Sexual functioning in patients with hepatocellular carcinoma. Cancer 2005; 104(10): 2234-43.
Hansen L, Rosenkranz SJ, Vaccaro GM, Chang MF. Patients with hepatocellular carcinoma near the end of life: a longitudinal qualitative study of their illness experiences. Cancer Nurs 2015; 38(4): E19-27.
Song H, Fang F, Valdimarsdóttir U, Lu D, Andersson TML, Hultman C, et al. Waiting time for cancer treatment and mental health among patients with newly diagnosed esophageal or gastric cancer: a nationwide cohort study. BMC Cancer 2017; 17(2): 1-9. doi10.1186/s12885-016-3013-7.
Wang ZX, Yuan CQ, Guan J, Liu SL, Sun CH, Kim SH. Factors associated with psychological characteristics in patients with hepatic malignancy before interventional procedures. Asian Pac J Cancer Prev 2012; 13(1): 309-14.
Sudarat B, Rachanee N, Varin B. Effectiveness of the nursing practice guideline on the anxiety of patients with advanced liver cancer. Thai Red Cross Nursing Journal 2017; 10(2): 74-86. (in Thai)
Paul C, Boyes A, Hall A, Bisquera A, Miller A, O'Brien L. The impact of cancer diagnosis and treatment on
employment, income, treatment decisions and financial assistance and their relationship to socioeconomic and disease factors. Support Care Cancer 2016; 24(11): 4739-46.
How to Cite
บทความที่ตีพิมพ์และแผนภูมิรูปภาพถือเป็นลิขสิทธิ์ของวารสารพยาบาลสาธารณสุข (Thai Public Health Nurses Association)